AGN — Argenica Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$32.11m
- AU$21.56m
- AU$0.51m
Annual income statement for Argenica Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.003 | 0.061 | 0.192 | 0.513 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.33 | 4.35 | 6.62 | 8.27 | 10.9 |
| Operating Profit | -1.33 | -4.35 | -6.56 | -8.08 | -10.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -4.09 | -4.82 | -5.48 | -7.17 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.03 | -4.09 | -4.82 | -5.48 | -7.17 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.03 | -4.09 | -4.82 | -5.48 | -7.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.03 | -4.09 | -4.82 | -5.48 | -7.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.012 | -0.054 | -0.054 | -0.053 | -0.055 |
| Dividends per Share |